Reata Pharmaceuticals, Inc. - (RETA) News
Filter RETA News Items
RETA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RETA News Highlights
- RETA's 30 day story count now stands at 2.
- Over the past 3 days, the trend for RETA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest RETA News From Around the Web
Below are the latest news stories about REATA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate RETA as an investment opportunity.
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Q3 2022 Earnings Call TranscriptReata Pharmaceuticals, Inc. (NASDAQ:RETA) Q3 2022 Earnings Call Transcript November 8, 2022 Reata Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-2.16, expectations were $-2.18. Operator: Thank you for standing by, and welcome to the Reata Pharmaceuticals Third Quarter 2022 Financial Results and Update on Development Programs Conference Call. An audio recording of today’s webcast […] |
15 Most Shorted Stocks Hedge Funds Are BuyingIn this article, we will discuss the 15 most shorted stocks hedge funds are buying. You can skip our detailed overview and go directly to the 5 Most Shorted Stocks Hedge Funds Are Buying. The year 2022 has been a dynamic year for financial markets worldwide. The equity markets have come under selling pressure across […] |
Reata Pharmaceuticals (NASDAQ:RETA) shareholders have endured a 84% loss from investing in the stock three years agoIt is a pleasure to report that the Reata Pharmaceuticals, Inc. ( NASDAQ:RETA ) is up 60% in the last quarter. But that... |
Results from Reata Pharmaceuticals Inc. (RETA) show potentialIn Tuesday’s session, Reata Pharmaceuticals Inc. (NASDAQ:RETA) marked $35.99 per share, up from $35.80 in the previous session. While Reata Pharmaceuticals Inc. has overperformed by 0.53%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RETA rose by 27.26%, with highs and lows ranging from $43.90 to […] |
Reata Pharmaceuticals, Inc. (RETA) Down 1.3% Since Last Earnings Report: Can It Rebound?Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Investing in Reata Pharmaceuticals Inc. (RETA) might be a great opportunity, but the stock is a bit overvaluedReata Pharmaceuticals Inc. (NASDAQ:RETA) closed Monday at $38.20 per share, up from $36.03 a day earlier. While Reata Pharmaceuticals Inc. has overperformed by 6.02%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RETA fell by -54.98%, with highs and lows ranging from $95.34 to $18.47, whereas […] |
Reata Pharmaceuticals To Jump 220%? Plus JP Morgan Predicts $51 For Las Vegas SandsGoldman Sachs boosted the price target on Reata Pharmaceuticals, Inc. (NASDAQ: RETA ) from $86 to $115. Goldman Sachs analyst Madhu Kumar maintained the stock with a Buy rating. Reata Pharmaceuticals shares rose 1.9% to close at $36.03 on Friday. RBC Capital slashed the price target on Edwards Lifesciences Corporation (NYSE: Full story available on Benzinga.com |
Investing in Reata Pharmaceuticals Inc. (RETA) might be an excellent idea, but the stock is currently overvalued/undervaluedThe share price of Reata Pharmaceuticals Inc. (NASDAQ:RETA) rose to $36.71 per share on Wednesday from $35.65. While Reata Pharmaceuticals Inc. has overperformed by 2.97%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RETA fell by -58.75%, with highs and lows ranging from $95.34 to $18.47, […] |
Reata Pharmaceuticals, Inc.'s stock is down 14%, but insiders still have about US$163k in profit after buying earlier this yearInsiders who purchased Reata Pharmaceuticals, Inc. ( NASDAQ:RETA ) shares in the past 12 months are unlikely to be... |
Can Reata Pharmaceuticals Inc. (NASDAQ: RETA) Still Be Considered A Loss When It’s Up 43.88% YTD?During the last session, Reata Pharmaceuticals Inc. (NASDAQ:RETA)’s traded shares were 0.85 million, with the beta value of the company hitting 1.19. At the end of the trading day, the stock’s price was $37.94, reflecting an intraday gain of 7.18% or $2.54. The 52-week high for the RETA share is $95.34, that puts it down … Can Reata Pharmaceuticals Inc. (NASDAQ: RETA) Still Be Considered A Loss When It’s Up 43.88% YTD? Read More » |